Boston Scientific (NYSE:BSX) unveiled a snapshot of its REDUCE-HTN clinical trial at EuroPCR this month, with interim data from the initial 41 patients treated with the company’s Vessix renal denervation system.
The data showed that these patients maintained "significant and sustained" reduction in blood pressure at 6 months following treatment, according to a company statement.
"The interim REDUCE-HTN data support the expected long-term benefit of the Vessix System in reducing blood pressure, and we’re excited to bring this advanced technology to physicians and their patients," peripheral interventions president Jeff Mirviss said in prepared remarks.
Renal denervation is a treatment for high blood pressure in which a balloon catheter is positioned in the blood vessels that lead to the kidneys and a radiofrequency disrupts the surrounding nerves.
Renal denervation technologies are currently the focus of much clinical attention for the potential to treat high blood pressure without drugs, may have a bonus side-effect of keeping heart rhythms in check.
The technology is making a big splash at this year’s EuroPCR meeting in Paris, where medtech giants have unveiled their own trial data supporting their respective renal denervation devices. Medtronic (NYSE:MDT) just wrapped up patient enrollment in a trial to support U.S. approval and rival St. Jude Medical (NYSE:STJ) is launching a new trial with its EnligHTN device.
